BridgeBio Pharma
BBIO
BBIO
181 hedge funds and large institutions have $1.44B invested in BridgeBio Pharma in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 48 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
10% more funds holding
Funds holding: 164 → 181 (+17)
2.87% more ownership
Funds ownership: 95.09% → 97.96% (+2.9%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
181
Holding in Top 10
3
Calls
$4.5M
Puts
$3.19M
Top Buyers
| 1 | +$11.3M | |
| 2 | +$10.4M | |
| 3 | +$9.63M | |
| 4 |
Renaissance Technologies
New York
|
+$9.48M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$7.26M |
Top Sellers
| 1 | -$30M | |
| 2 | -$3.98M | |
| 3 | -$3.09M | |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.04M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$2.97M |